Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

1.

Antiprogestins in gynecological diseases.

Goyeneche AA, Telleria CM.

Reproduction. 2015 Jan;149(1):R15-33. doi: 10.1530/REP-14-0416. Epub 2014 Sep 24. Review.

2.

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity.

Gamarra-Luques CD, Hapon MB, Goyeneche AA, Telleria CM.

J Ovarian Res. 2014 Apr 27;7:45. doi: 10.1186/1757-2215-7-45. eCollection 2014.

3.

Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics.

Brandhagen BN, Tieszen CR, Ulmer TM, Tracy MS, Goyeneche AA, Telleria CM.

BMC Cancer. 2013 Jan 26;13:35. doi: 10.1186/1471-2407-13-35.

4.

Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.

Gamarra-Luques CD, Goyeneche AA, Hapon MB, Telleria CM.

BMC Cancer. 2012 Jun 22;12:200. doi: 10.1186/1471-2407-12-200.

5.

Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.

Tieszen CR, Goyeneche AA, Brandhagen BN, Ortbahn CT, Telleria CM.

BMC Cancer. 2011 May 27;11:207. doi: 10.1186/1471-2407-11-207.

6.

Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.

Goyeneche AA, Seidel EE, Telleria CM.

Invest New Drugs. 2012 Jun;30(3):967-80. doi: 10.1007/s10637-011-9655-z. Epub 2011 Mar 22.

7.

Involvement of Akt, Ras and cell cycle regulators in the potential development of endometrial hyperplasia in women with polycystic ovarian syndrome.

Villavicencio A, Goyeneche A, Telleria C, Bacallao K, Gabler F, Fuentes A, Vega M.

Gynecol Oncol. 2009 Oct;115(1):102-7. doi: 10.1016/j.ygyno.2009.06.033. Epub 2009 Jul 23.

8.

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

Arribas JR, Delgado R, Arranz A, Muñoz R, Portilla J, Pasquau J, Pérez-Elias MJ, Iribarren JA, Rubio R, Ocampo A, Sánchez-Conde M, Knobel H, Arazo P, Sanz J, López-Aldeguer J, Montes ML, Pulido F; OK04 Study Group.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):147-52. doi: 10.1097/QAI.0b013e3181a56de5.

PMID:
19349870
9.

Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity.

Freeburg EM, Goyeneche AA, Seidel EE, Telleria CM.

Cancer Cell Int. 2009 Feb 17;9:4. doi: 10.1186/1475-2867-9-4.

10.

Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment.

Freeburg EM, Goyeneche AA, Telleria CM.

Int J Oncol. 2009 Mar;34(3):743-55.

11.

Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.

Goyeneche AA, Carón RW, Telleria CM.

Clin Cancer Res. 2007 Jun 1;13(11):3370-9.

12.

Cell death induced by serum deprivation in luteal cells involves the intrinsic pathway of apoptosis.

Goyeneche AA, Harmon JM, Telleria CM.

Reproduction. 2006 Jan;131(1):103-11.

13.
15.

In vivo hormonal environment leads to differential susceptibility of the corpus luteum to apoptosis in vitro.

Goyeneche AA, Martinez IL, Deis RP, Gibori G, Telleria CM.

Biol Reprod. 2003 Jun;68(6):2322-30. Epub 2003 Feb 5.

16.

Progesterone promotes survival of the rat corpus luteum in the absence of cognate receptors.

Goyeneche AA, Deis RP, Gibori G, Telleria CM.

Biol Reprod. 2003 Jan;68(1):151-8.

17.

Androstenedione interferes in luteal regression by inhibiting apoptosis and stimulating progesterone production.

Goyeneche AA, Calvo V, Gibori G, Telleria CM.

Biol Reprod. 2002 May;66(5):1540-7.

18.

Apoptosis induced by antigestagen RU486 in rat corpus luteum of pregnancy.

Telleria CM, Goyeneche AA, Cavicchia JC, Stati AO, Deis RP.

Endocrine. 2001 Jul;15(2):147-55.

PMID:
11720240
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk